Improving treatment for blood cancers in ovarian cancer survivors
Official title: Therapy of PARP inhibitor-associated myeloid neoplasms in ovarian cancer patients
Funded at Mayo Clinic Rochester · NIH-11082268 · Data updated 2026-11-12
This study is looking for better treatment options for ovarian cancer patients who develop serious blood disorders after using certain medications, especially those with a specific gene mutation that makes standard treatments less effective, so they can live longer and feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $466,152 |
| NIH project number | 5R01CA289285-02 |
| Project ID | NIH-11082268 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are ovarian cancer survivors who have developed therapy-related myeloid neoplasms after receiving PARP inhibitor treatment.
✕Less likely to help
Patients who have not received PARP inhibitors or who do not have therapy-related myeloid neoplasms may not benefit from this research.
What this research studies
This research focuses on therapy-related myeloid neoplasms (tMNs), which are serious blood disorders that can develop in ovarian cancer patients who have undergone treatment with PARP inhibitors. The study aims to explore new therapeutic approaches to improve outcomes for these patients, particularly those with mutations in the TP53 gene, which are associated with poor responses to standard chemotherapy. By investigating the use of replication checkpoint modulators, the research seeks to find more effective treatments that could extend survival and improve quality of life for affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ovarian cancer survivors who develop severe blood cancers, potentially improving their survival rates.
How similar studies have gone: Previous research has shown promising results in treating similar blood cancers, indicating that this approach may lead to significant advancements in therapy.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Kaufmann, Scott H — Mayo Clinic Rochester
- Study coordinator: Kaufmann, Scott H
Related research
Other NIH-funded projects on the same topics.
-
Early blood changes and treatment-related leukemia risk after ovarian cancer
This project follows ovarian cancer survivors to look for early blood cell changes that can lead to treatment-related leukemia.
-
Treating bone marrow cancers linked to PARP inhibitor use in ovarian cancer survivors
Researchers are developing new drug strategies to treat aggressive bone marrow cancers that can occur after PARP inhibitor therapy in ovarian cancer survivors.
-
Investigating blood disorders in ovarian cancer survivors
This study is looking at how treatments for ovarian cancer might cause blood disorders later on, and it's for ovarian cancer survivors who want to help researchers find ways to prevent these issues and improve future treatments.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.